Loading
Every dated change on the records linked to High-grade serous ovarian cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Objective responses in about a third of patients with folate receptor alpha-high platinum-resistant ovarian cancer; accelerated approval in November 2022.
A milestone in how this cancer is treated.